Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
13 Oktober 2023 - 2:00PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced upcoming data presentations for tenapanor for
hyperphosphatemia at the American Society of Nephrology (ASN)
Kidney Week 2023 meeting to be held in Philadelphia, PA, November
1-5, 2023. XPHOZAH (tenapanor), discovered and developed by
Ardelyx, is an investigational first-in-class phosphate absorption
inhibitor.
Ardelyx will present four poster presentations highlighting data
from two trials in patients with hyperphosphatemia on maintenance
dialysis in the U.S. Additionally, the company’s collaboration
partner for tenapanor in Japan, Kyowa Kirin Co, Ltd. (Kyowa Kirin),
will present key results from two Phase 3 studies of tenapanor in a
similar patient population in Japan.
Information regarding ASN's Kidney Week, including copies of
presentation abstracts, can be found at
https://www.asn-online.org/education/kidneyweek.
Ardelyx Poster Presentations:
Title:
Optimal Initiation of Tenapanor Treatment Analyzed by
Baseline Phosphate Binder Dose: A Sub-analysis of the OPTIMIZE
Study |
Authors: |
Stuart Sprague, Jill Meyer, David Rosenbaum, Susan Edelstein, Yang
Yang, Suling Zhao, David Spiegel |
Poster Number: |
TH-PO143 |
Date/Time: |
November 2, 2023 from 10:00 AM to
12:00 PM ET |
Title:
Patient Education Improves Tenapanor Tolerability in
OPTIMIZE Study |
Authors: |
Stephen Fadem, David Tietjen, David Spiegel, Susan Edelstein, Yang
Yang, David Rosenbaum |
Poster Number: |
TH-PO147 |
Date/Time: |
November 2, 2023 from 10:00 AM to
12:00 PM ET |
Title: Safety
Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in
Patients on Maintenance Dialysis with
Hyperphosphatemia |
Authors: |
Arnold Silva, German T. Hernandez, David Spiegel, David Rosenbaum,
Susan Edelstein, Yang Yang, Suling Zhao, Laura Williams |
Poster Number: |
TH-PO146 |
Date/Time: |
November 2, 2023 from 10:00 AM to
12:00 PM ET |
Title:
Tenapanor in Combination with Phosphate Binders Improves
Short and Long- Term Control of Serum Phosphate (sP) in Patients on
Dialysis with Hyperphosphatemia |
Authors: |
Daniel Weiner, Robert Lynn, David
Spiegel, Susan Edelstein, Yang Yang, David Rosenbaum |
Poster Number: |
FR-PO318 |
Date/Time: |
November 3, 2023 from 10:00 AM to
12:00 PM |
Kyowa Kirin Poster Presentations:
Title:
Tenapanor effect on decrease in phosphate binder pill
burden for hyperphosphatemia in Japanese patients undergoing
hemodialysis: A phase 3 long-term study |
Poster Number: |
TH-PO144 |
Date/Time: |
November 2, 2023 from 10:00 AM to
12:00 PM |
Title:
Efficacy and safety of tenapanor in Japanese peritoneal
dialysis patients with hyperphosphatemia: Results of a phase 3
study |
Poster Number: |
TH-PO145 |
Date/Time: |
November 2, 2023 from 10:00 AM to
12:00 PM |
About Ardelyx, Inc.Ardelyx was founded with a
mission to discover, develop, and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs.
Ardelyx’s first approved product, IBSRELA® (tenapanor) is available
in the United States and Canada. Ardelyx is also developing
XPHOZAH® (tenapanor). Ardelyx has a Phase 2 potassium lowering
compound, RDX013, for the potential treatment of elevated serum
potassium, or hyperkalemia, a problem among certain patients with
kidney and/or heart disease and an early-stage program in metabolic
acidosis, a serious electrolyte disorder in patients with CKD.
Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun
Pharma in China and Knight Therapeutics in Canada for the
development and commercialization of tenapanor in their respective
territories. For more information, please visit
https://ardelyx.com/ and connect with us on X (formerly Twitter),
LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Kimia Keshtbod kkeshtbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024